Introduction:

The introduction of structured treatment interruptions and delayed onset to treatment is expected to result in a gradual decline in HIV market growth during the next 5-7 years. As treatment strategies become more complex, physicians will turn towards pharmaceutical companies for drugs with simpler dosing profiles. This In-Depth Commercial Analysis provides a thorough review of current drug use, SWOT analyses of marketed products, and a discussion of the life cycle of a typical HIV therapeutic. 

Scope:

* Global sales data for all currently marketed drugs, with estimates for 2002 revenue 

* Forecasts of drug sales for all currently marketed drugs through to 2010 

* SWOT analyses for all currently marketed drugs 

* Analysis of life cycle management of HIV drugs 

* Discussion of the impact of generic competition on the HIV market, through comparisons with the oncology market 

Report Highlights:

Market impacts, such as the introduction of structured treatment interruptions (STIs) and delayed onset to treatment, will cause a gradual decline in HIV market growth during the next 5-7 years 

Datamonitor believes that revenues of branded products within the developed world will not be significantly affected by generic competition through to 2010 

Reasons to Purchase:

* Identify which antiretroviral drug classes have the potential to show the greatest market growth to 2010 

* Predict the impact of generics on the antiretroviral markets, as the current market leading products lose patent protection 

* Understand how the simplification of therapy regimens and the need to reduce drug-associated side effects will drive development of novel products 

* Target the patient segments with the greatest unmet needs 

 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a175